Recent technological developments of new smoke-free products such as heated tobacco products, e-vapor products, and oral nicotine pouches that have the potential to provide nicotine with fewer and lower levels of harmful chemicals compared with combustible products like cigarettes have made it possible to offer a portfolio of smoke-free products to adult smokers who would otherwise continue to smoke as alternatives to cigarettes and other combusted products.
Nicotine pouches are a relatively new addition to the market of oral nicotine products and have been present on the U.S. market since 2016 and in Europe since 2018. These pouches are similar to snus but do not contain tobacco. Instead, nicotine pouches contain tobacco-derived or synthetic nicotine, flavorings, and other ingredients.
The scientific assessment of oral products, like nicotine pouches, that substantiates the reduced-risk potential includes characterization of the chemical composition of the product, pre-clinical and clinical toxicological assessments, and product use characterization.
In this presentation we discuss the low-risk potential of nicotine pouches and their place in the risk continuum of tobacco and nicotine-containing products.